Therapeutic use of the Arts for Patients with Multiple Sclerosis

Diabetic striatopathy (DS) is a rare hyperglycaemic condition associated with one or both of the following criteria: (1) acute-onset chorea–ballism (random, flowing and nonsuppressible involuntary movements) and (2) striatal hyperdensity on computed tomography (CT) scan or T1-weighted magnetic resonance imaging (...

Multiple sclerosis (MS) is a complex disease that can pose significant challenges in diagnosis, monitoring and treatment. Over the years, the quest for more precise and accessible diagnostic tools has led to the exploration of different fluid biomarkers in cerebrospinal ...

In the latest edition of touchREVIEWS in Neurology, we are pleased to present a collection of insightful articles that highlight the current landscape and future directions in neurological research and treatment. Firstly, Rajvinder Karda opens this issue with a compelling ...

Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system characterized by inflammation, demyelination and neurodegeneration. Natalizumab is a widely used anti-α4 integrin inhibitor for treating highly active MS. In the pivotal trials of natalizumab for MS, ...

Acute disseminated encephalomyelitis (ADEM), first characterized in 1931,1 is a non-specific clinical syndrome of polyfocal central nervous system (CNS) inflammatory demyelination; it is characterized by encephalopathy and large, poorly demarcated cerebral white matter lesions.2,3 Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), ...

Welcome to our new issue of touchREVIEWS in Neurology, which features a wide range of topical articles covering various areas of neurology. We begin with two practice pearls. The first from Garg et al., focusses on the increasingly important subject ...

Over the past two decades, monoclonal antibodies targeting the surface antigen CD20 have emerged as highly effective disease-modifying therapies (DMTs) for multiple sclerosis (MS).1 The major mechanism of action of these therapies is via B-cell depletion, as CD20 is expressed ...

Disease-modifying therapies (DMTs) have brought about substantial improvements to the lives of people with multiple sclerosis (MS).1–3 However, MS remains a chronic disease with a variable course and symptoms, representing a substantial challenge to quality of life.2,3 MS management requires ...

Although disease-modifying therapies have been the primary focus of multiple sclerosis (MS) treatment during the past two decades, there is increasing awareness of the importance of treating patients holistically, paying attention to functional comorbidities and addressing mood and cognition. In ...

Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease affecting approximately 2.5 million individuals worldwide.1,2 Pathologically, MS is mostly characterized by inflammation, demyelination, axonal degeneration and gliosis. Clinically, a wide range of symptoms can occur, including cognitive, motor and sensory impairments.3 The ...

Paediatric-onset multiple sclerosis (POMS) is the symptom onset and diagnosis of multiple sclerosis (MS) before the age of 18.1 Diagnostic criteria were revised by the International Pediatric MS Study Group in 2013. Compared to patients with adult-onset MS (AOMS), young patients are ...

Multiple sclerosis (MS) is a chronic neurological disease that is associated with high rates of depression and anxiety,1 particularly in the early stages of diagnosis.2,3 A growing body of evidence suggests that cognitive behavioural therapy (CBT) is an effective treatment ...